| Abstract: |
Autoimmune diseases (AIDs) are common with a worldwide prevalence estimated at 5%. It can affect any organ and while heterogeneous in manifestations and severity, all AIDs degrade quality of life. Autologous hematopoietic cell transplant (HCT) has been used to treat patients with severe and refractory AID for the last 20 years. Allogeneic HCT is rarely used for patients with AID because of its substantial treatment related mortality and the limited data regarding disease control. The indications for autologous HCT are based on clinical trial experience and registry data. The predominant indications for HCT have evolved over time, in part, due to the introduction of alternative therapies. Currently, the most common indications are MS, systemic sclerosis (SSc), Crohn's disease (CD), and autoimmune cytopenias. Patients with AID may experience complications that are not typical for those undergoing autologous HCT for lymphomas or multiple myeloma. © 2017 John Wiley & Sons Ltd. All rights reserved. |
